FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156260219> ?p ?o ?g. }

• W3156260219 endingPage "3258" @default.
• W3156260219 startingPage "3258" @default.
• W3156260219 abstract "Abstract Introduction: Serious viral infections that occur as a consequence of poor or delayed endogenous immune reconstitution are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). In the post HSCT setting immune reconstitution is currently evaluated by phenotypic profiling to assess lymphocytes subset recovery over time. However, these studies fail to assess either the functional capacity or antigen specificity of the reconstituting cells. We hypothesized that utilizing functional assays in combination with phenotypic assessments would enable the rapid and accurate risk-stratification of allogeneic HSCT recipients into those whose endogenous immunity was sufficient to deal with viral challenge versus those requiring clinical intervention with targeted antiviral therapies. Methods: To evaluate phenotypic and functional immune response post-HSCT, we performed a prospective study in pediatric HSCT recipients where we monitored the frequency (by flow cytometry) and function of T cells directed against immunogenic antigens for the most common viruses detected post-transplant (CMV, EBV, HHV-6, Adenovirus, BK virus) using IFNg ELIspot assays. Assessments were performed at least monthly for up to 6 months post-transplant and weekly in patients who developed a viral reactivation post-HSCT. Results: To date we have enrolled 23 allogeneic HSCT recipients, ages 3 to 16 years. Of these, 9 received a matched related donor graft (MRD), 13 received a matched/mismatched unrelated donor graft (MUD/MMUD) and 1 patient received a cord blood (CB) donor graft. All patients underwent myeloablative conditioning for a spectrum of underlying malignant (ALL - 10, AML - 4, MDS - 2) and non-malignant diagnoses (Hemoglobinopathy - 3, SAA/Marrow failure - 4, immune deficiency - 1). Based on donor type used for transplant and underlying diagnosis, 15 of these patients received T-cell depleting conditioning regimens using Alemtuzumab for in-vivo T-cell depletion while 8 patients did not receive T-cell depletion as part of their conditioning regimen. In patients who received a non-T-cell depleting conditioning regimen immune reconstitution was rapid with recovery to a median of 524 CD3+ T cells counts/µL by day 30 post-transplant (range 333-1711) [months 2, 3, 4, 5, 6 of 1090, 1382, 2184, 2077, 2481 cells/µL, respectively; n=8]. In contrast, for patients that received T-cell depleting conditioning regimens, reconstitution was significantly slower with median CD3 T-cell counts/µL of 0 (range: 0-249) by day 30 and recovery to 500 cells/µL occurring on or after month 5 post-transplant (months 2, 3, 4, 5, 6 of 19, 138, 147, 516, 836 cells/µL, respectively; n=15). In total, we detected 32 episodes of viral infection/reactivation [CMV (n=12), EBV (n=10), HHV-6 (n=5), Adenovirus (n=3) and BK (n=2)]. Twenty four occurred in our T-cell depleted transplant recipients, while 8 in non-T-cell depleted transplant recipients. By measuring functional virus-specific T cell recovery by IFNg ELIspot assays, we were able to identify infections that could be endogenously controlled (n=23) and those that could not (n=9). This allowed for rapid intervention with additional antiviral agents in patients that could not control their infections. Of these, 3 received ‘off the shelf’ CMV-specific T cells to treat persistent and drug refractory CMV viremia. Conclusion: Screening for virus-specific T-cell responses with IFNg ELIspot assays allowed us to risk-stratify and tailor therapy for 23 pediatric HSCT recipients with viral infection/reactivation. Our encouraging results warrant further exploration in a larger cohort of patients. Disclosures Leen: ViraCyte LLC: Equity Ownership." @default.
• W3156260219 created "2021-04-26" @default.
• W3156260219 creator A5019869101 @default.
• W3156260219 creator A5020956671 @default.
• W3156260219 creator A5033931027 @default.
• W3156260219 creator A5036222762 @default.
• W3156260219 creator A5048434448 @default.
• W3156260219 creator A5056105964 @default.
• W3156260219 creator A5057319695 @default.
• W3156260219 creator A5076234152 @default.
• W3156260219 date "2017-12-07" @default.
• W3156260219 modified "2023-09-29" @default.
• W3156260219 title "Towards Functional Immune Monitoring in Allogeneic Hematopoietic Stem Cell Transpant Recipients" @default.
• W3156260219 doi "https://doi.org/10.1182/blood.v130.suppl_1.3258.3258" @default.
• W3156260219 hasPublicationYear "2017" @default.
• W3156260219 type Work @default.
• W3156260219 sameAs 3156260219 @default.
• W3156260219 citedByCount "0" @default.
• W3156260219 crossrefType "journal-article" @default.
• W3156260219 hasAuthorship W3156260219A5019869101 @default.
• W3156260219 hasAuthorship W3156260219A5020956671 @default.
• W3156260219 hasAuthorship W3156260219A5033931027 @default.
• W3156260219 hasAuthorship W3156260219A5036222762 @default.
• W3156260219 hasAuthorship W3156260219A5048434448 @default.
• W3156260219 hasAuthorship W3156260219A5056105964 @default.
• W3156260219 hasAuthorship W3156260219A5057319695 @default.
• W3156260219 hasAuthorship W3156260219A5076234152 @default.
• W3156260219 hasConcept C126322002 @default.
• W3156260219 hasConcept C147483822 @default.
• W3156260219 hasConcept C203014093 @default.
• W3156260219 hasConcept C2776090121 @default.
• W3156260219 hasConcept C2777408962 @default.
• W3156260219 hasConcept C2779053233 @default.
• W3156260219 hasConcept C2780914630 @default.
• W3156260219 hasConcept C28328180 @default.
• W3156260219 hasConcept C2911091166 @default.
• W3156260219 hasConcept C54355233 @default.
• W3156260219 hasConcept C71924100 @default.
• W3156260219 hasConcept C86803240 @default.
• W3156260219 hasConcept C8891405 @default.
• W3156260219 hasConceptScore W3156260219C126322002 @default.
• W3156260219 hasConceptScore W3156260219C147483822 @default.
• W3156260219 hasConceptScore W3156260219C203014093 @default.
• W3156260219 hasConceptScore W3156260219C2776090121 @default.
• W3156260219 hasConceptScore W3156260219C2777408962 @default.
• W3156260219 hasConceptScore W3156260219C2779053233 @default.
• W3156260219 hasConceptScore W3156260219C2780914630 @default.
• W3156260219 hasConceptScore W3156260219C28328180 @default.
• W3156260219 hasConceptScore W3156260219C2911091166 @default.
• W3156260219 hasConceptScore W3156260219C54355233 @default.
• W3156260219 hasConceptScore W3156260219C71924100 @default.
• W3156260219 hasConceptScore W3156260219C86803240 @default.
• W3156260219 hasConceptScore W3156260219C8891405 @default.
• W3156260219 hasLocation W31562602191 @default.
• W3156260219 hasOpenAccess W3156260219 @default.
• W3156260219 hasPrimaryLocation W31562602191 @default.
• W3156260219 hasRelatedWork W1521634924 @default.
• W3156260219 hasRelatedWork W1540606775 @default.
• W3156260219 hasRelatedWork W2026575981 @default.
• W3156260219 hasRelatedWork W2050858563 @default.
• W3156260219 hasRelatedWork W2074503110 @default.
• W3156260219 hasRelatedWork W2132312965 @default.
• W3156260219 hasRelatedWork W2137557951 @default.
• W3156260219 hasRelatedWork W2309520817 @default.
• W3156260219 hasRelatedWork W2343715259 @default.
• W3156260219 hasRelatedWork W2532059005 @default.
• W3156260219 hasRelatedWork W2545428814 @default.
• W3156260219 hasRelatedWork W2559398249 @default.
• W3156260219 hasRelatedWork W2755802159 @default.
• W3156260219 hasRelatedWork W2785065779 @default.
• W3156260219 hasRelatedWork W2895510075 @default.
• W3156260219 hasRelatedWork W2980044986 @default.
• W3156260219 hasRelatedWork W3012774241 @default.
• W3156260219 hasRelatedWork W3016329771 @default.
• W3156260219 hasRelatedWork W3108073870 @default.
• W3156260219 hasRelatedWork W3137446827 @default.
• W3156260219 hasVolume "130" @default.
• W3156260219 isParatext "false" @default.
• W3156260219 isRetracted "false" @default.
• W3156260219 magId "3156260219" @default.
• W3156260219 workType "article" @default.